These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 21286011)

  • 1. DNA methylation changes following 5-azacitidine treatment in patients with myelodysplastic syndrome.
    Tran HT; Kim HN; Lee IK; Kim YK; Ahn JS; Yang DH; Lee JJ; Kim HJ
    J Korean Med Sci; 2011 Feb; 26(2):207-13. PubMed ID: 21286011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Epigenetic therapy in myelodysplastic syndromes (MDS). Treatment with DNA methyltransferase inhibitors].
    Daskalakis M; Blagitko-Dorfs N; Hackanson B; Lübbert M
    Pharm Unserer Zeit; 2010 May; 39(3):217-27. PubMed ID: 20425776
    [No Abstract]   [Full Text] [Related]  

  • 3. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment.
    Daskalakis M; Nguyen TT; Nguyen C; Guldberg P; Köhler G; Wijermans P; Jones PA; Lübbert M
    Blood; 2002 Oct; 100(8):2957-64. PubMed ID: 12351408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing patients with higher-risk myelodysplastic syndrome with stable disease on hypomethylating agents.
    Sekeres MA
    Leuk Lymphoma; 2015; 56(12):3267-9. PubMed ID: 26077360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of DNA methyltransferase inhibitors for the treatment of myelodysplastic syndromes.
    Tohyama K
    Curr Pharm Des; 2012; 18(22):3190-7. PubMed ID: 22571698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk myelodysplastic syndrome].
    Maeda Y
    Rinsho Ketsueki; 2014 Oct; 55(10):1870-81. PubMed ID: 25297751
    [No Abstract]   [Full Text] [Related]  

  • 7. Droplet digital PCR for the quantification of Alu methylation status in hematological malignancies.
    Orsini P; Impera L; Parciante E; Cumbo C; Minervini CF; Minervini A; Zagaria A; Anelli L; Coccaro N; Casieri P; Tota G; Brunetti C; Ricco A; Carluccio P; Specchia G; Albano F
    Diagn Pathol; 2018 Dec; 13(1):98. PubMed ID: 30579366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA Methyltransferase Inhibitors in Myeloid Cancer: Clonal Eradication or Clonal Differentiation?
    Ørskov AD; Grønbæk K
    Cancer J; 2017; 23(5):277-285. PubMed ID: 28926428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes.
    Khan H; Vale C; Bhagat T; Verma A
    Semin Hematol; 2013 Jan; 50(1):16-37. PubMed ID: 23507481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene Expression and DNA Methylation Profiling Suggest Potential Biomarkers for Azacitidine Resistance in Myelodysplastic Syndrome.
    Kim DY; Shin DY; Oh S; Kim I; Kim EJ
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndrome.
    Gore SD
    Hematology Am Soc Hematol Educ Program; 2011; 2011():550-5. PubMed ID: 22160088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?
    Lowder JN; Taverna P; Issa JP
    Epigenomics; 2015 Oct; 7(7):1083-8. PubMed ID: 26541345
    [No Abstract]   [Full Text] [Related]  

  • 13. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.
    Griffiths EA; Gore SD
    Semin Hematol; 2008 Jan; 45(1):23-30. PubMed ID: 18179966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic therapies move into new territory, but how exactly do they work?
    Tuma RS
    J Natl Cancer Inst; 2009 Oct; 101(19):1300-1. PubMed ID: 19755677
    [No Abstract]   [Full Text] [Related]  

  • 15. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
    Estey EH
    Leukemia; 2013 Sep; 27(9):1803-12. PubMed ID: 23757301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action.
    Lübbert M
    Curr Top Microbiol Immunol; 2000; 249():135-64. PubMed ID: 10802943
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes.
    Sekeres MA; List AF; Cuthbertson D; Paquette R; Ganetzky R; Latham D; Paulic K; Afable M; Saba HI; Loughran TP; Maciejewski JP
    J Clin Oncol; 2010 May; 28(13):2253-8. PubMed ID: 20354132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moleculary Confirmed, Cytogenetic Remission in a Case with Myelodysplastic Syndrome Treated with Azacitidne.
    Panovska-Stavridis I; Ivanovski M; Trajkova S; Pivkova-Veljanovska A; Popova-Labaceska M; Matevska-Geshovska N; Noveski P; Plaseska-Karanfilska D; Cevreska L; Dimovski AJ
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2017 Dec; 38(3):157-162. PubMed ID: 29668469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Azacitidine regulates DNA methylation of GADD45γ in myelodysplastic syndromes.
    Yang Y; Li J; Geng Y; Liu L; Li D
    J Clin Lab Anal; 2021 Feb; 35(2):e23597. PubMed ID: 33080073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Digging deep into "dirty" drugs - modulation of the methylation machinery.
    Pleyer L; Greil R
    Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.